Table 2.
Codon | SNPs | Prevalence | Frequency | ||||
---|---|---|---|---|---|---|---|
Evaluable sample (N) | Number with specific SNP (n) | % (n/N × 100) | Evaluable sample (N) | Number with specific SNP (n) | % (n/N × 100) | ||
Pfdhfr | |||||||
50/51 | CN | 142 | 36 | 25.5 | 136 | 33 | 24.3 |
CI | 142 | 106 | 75.5 | 136 | 103 | 75.7 | |
59 | C | 146 | 24 | 16.4 | 140 | 21 | 15.0 |
R | 146 | 122 | 83.6 | 140 | 119 | 85.0 | |
108 | S | 139 | 17 | 12.2 | 139 | 17 | 12.2 |
N | 139 | 122 | 87.8 | 139 | 122 | 87.8 | |
T | 0 | 0 | |||||
164 | I | 132 | 132 | 100.0 | 132 | 132 | 100.0 |
L | 0 | 0 | |||||
Pfdhps | |||||||
436/437 | AA | 147 | 3 | 2.0 | 141 | 3 | 2.1 |
AG | 95 | 64.6 | 95 | 67.4 | |||
SA | 3 | 2.0 | 1 | 0.7 | |||
SG | 45 | 30.6 | 41 | 29.1 | |||
FA | 1 | 0.7 | 1 | 0.7 | |||
540 | K | 143 | 142 | 99.3 | 141 | 141 | 100.0 |
E | 1 | 0.7 | 0 | ||||
581 | A | 152 | 147 | 96.7 | 150 | 146 | 97.3 |
G | 5 | 3.3 | 4 | 2.7 | |||
613 | A | 148 | 138 | 93.2 | 146 | 137 | 93.8 |
S | 10 | 6.8 | 9 | 6.2 | |||
Pfdhfr and Pfdhps haplotypes* | |||||||
Pfdhfr† (N = 126) | |||||||
CIRNI | 97 | 77 | |||||
CNCSI | 9 | 7.1 | |||||
Pfhdps (N = 130) | |||||||
AGKAA | 80 | 61.5 | |||||
SGKAA | 39 | 30 | |||||
AGKAS | 6 | 4.6 | |||||
AGKGS | 1 | 0.8 | |||||
AAKAA | 3 | 2.3 | |||||
SAKAA | 1 | 0.8 | |||||
Pfdhfr/ (N = 81) | |||||||
CIRNI/AGKAA (quadruple mutation) | 42 | 51.9 | |||||
CIRNI/SGKAA (quadruple mutation) | 33 | 40.7 | |||||
CIRNI/AGKAS (quintuple mutation) | 5 | 6.2 | |||||
CIRNI/AGKGS (sextuple mutation) | 1 | 1.2 |
SNPs = single nucleotide polymorphisms.
Only frequencies are reported for haplotypes and N is evaluable samples whereas n is the number of haplotypes.
The Pfdhfr double mutations (CNRNI + CICNI + CIRSI) collectively constituted 15.9%.